Skip to main content

Sachs Bruce I's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Jul 18, 2023

Accession no.
0001209191-23-042566
Filed
Jul 18, 2023
Trade date
Jul 14-17, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.01M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sachs Bruce ICIK 0001197036Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 17, 2023Common StockMOption exerciseAcquired+11,250$127.54+$1,434,82551,250Direct
Jul 17, 2023Common StockSSaleDisposed−1,697$355.54F2,F3−$603,351.3849,553Direct
Jul 17, 2023Common StockSSaleDisposed−5,711$356.75F2,F4−$2,037,399.2543,842Direct
Jul 17, 2023Common StockSSaleDisposed−3,842$357.29F2,F5−$1,372,708.1840,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 14, 2023Common StockAGrant or awardAcquired+124.72$350.79+$43,750.5314,524.97Direct
Jul 17, 2023Common StockMOption exerciseDisposed−11,250$0.00$011,250Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 3 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $355.54 (range $355.00 to $355.97).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $356.75 (range $356.00 to $356.99).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $357.29 (range $357.00 to $357.38).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)